secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2021-11-16T23:59:59+00:00
Accession:  0001193125-21-331369
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Roche terminates license agreement for AT-527 with Atea; effective Feb 10, 2022
-------------------------------------------------------------------------------

- Roche sent termination notice on Nov 12, 2021; license ends Feb 10, 2022.
- Agreement covered ex-U.S. rights to develop and commercialize AT-527.
- No early termination penalties will be incurred by Atea.
- Atea retains full rights to AT-527 outside the terminated pact.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312521331369/0001193125-21-331369-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312521331369/d368899d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-331369

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer